INTRODUCTION

Opitz syndrome (OS; MIM 145410 and 300000) is also known as hypertelorism-hypospadias syndrome, and it is a congenital midline malformation syndrome that was formerly reported as two separate entities, G and BBB syndromes (1, 2). The constellation of clinical manifestations that define OS include: 1) congenital heart defects such as atrial and ventricular septal defects, patent ductus arteriosus and coarctation of the aorta; 2) a characteristic facial appearance (a broad nasal bridge, hypertelorism and low-set posteriorly rotated ears) with labiopalatine and laryngotracheal abnormalities; 3) dysphagia and gastro-oesophageal reflux; 4) abnormalities of the central nervous system (including major motor skill defects and delayed development); and 5) genital anomalies, e.g. hypospadias (3).

OS is genetically heterogeneous because it has both an X-linked (Xp22.3) and an autosomal (22q11.2) loci (4). The gene responsible for X-linked OS (XLOS) is the MID1 gene which encodes a microtubule-associated RING-Bbox-Coiled-coil (RBCC) protein. We recently found a four-year Korean male patient who was suspected of having XLOS. Mutation analysis of the MID1 gene in the patient and his mother demonstrated that the patient had a novel insertion mutation (c.1798_1799-1insC), and his mother was a heterozygous carrier of the mutation. After identification of the causative mutation in this family, prenatal diagnosis of two consecutive fetuses were successfully undertaken. This is the first report on a genetically confirmed case of XLOS in Korea.
Table 1. Clinical findings of the patient and his mother with the MID1 gene mutation

| Phenotype                               | This study | Reported frequency of each phenotype (%) |
|-----------------------------------------|------------|-----------------------------------------|
| Hypertelorism/telecanthus               | Present    | Male with MID1 mutation 98.0% 100.0%     |
|                                         |            | Female with MID1 mutation 41.7% 20.0%    |
|                                         |            | (48/49) (18/18)                         |
| Broad nasal bridge                      | Present    | Male with MID1 mutation 15.7% 20.0%     |
|                                         |            | Female with MID1 mutation 13.1% 11.1%   |
|                                         |            | (15/36) (2/10)                          |
| Anteverted nares                        | Absent     | Male with MID1 mutation 37.1% 11.1%     |
|                                         |            | Female with MID1 mutation 24.2% 30.0%   |
|                                         |            | (13/35) (1/9)                           |
| Cleft lip and/or palate                 | Absent     | Male with MID1 mutation 52.2% 30.0%     |
|                                         |            | Female with MID1 mutation 24.2% 30.0%   |
|                                         |            | (24/46) (3/10)                          |
| High arched palate                      | Present    | Male with MID1 mutation 54.2% 30.0%     |
|                                         |            | Female with MID1 mutation 21.3% 20.0%   |
|                                         |            | (26/48) (3/10)                          |
| Laryngotracheoesophageal anomaly        | Present    | Male with MID1 mutation 26.1% 20.0%     |
|                                         |            | Female with MID1 mutation 26.1% 11.1%   |
|                                         |            | (13/36) (1/9)                           |
| Dysphagia/gastroesophageal reflux       | Present    | Male with MID1 mutation 54.2% 30.0%     |
|                                         |            | Female with MID1 mutation 21.3% 20.0%   |
|                                         |            | (26/48) (3/10)                          |
| Cardiac structural defects              | Absent     | Male with MID1 mutation 26.1% 20.0%     |
|                                         |            | Female with MID1 mutation 26.1% 11.1%   |
|                                         |            | (13/36) (1/9)                           |
| Anal atresia/anal canal                  | Absent     | Male with MID1 mutation 54.2% 30.0%     |
|                                         |            | Female with MID1 mutation 21.3% 20.0%   |
|                                         |            | (26/48) (3/10)                          |
| Hypospadias                             | Absent     | Male with MID1 mutation 26.1% 20.0%     |
|                                         |            | Female with MID1 mutation 26.1% 11.1%   |
|                                         |            | (13/36) (1/9)                           |
| Genitourinary defects                   | Absent     | Male with MID1 mutation 54.2% 30.0%     |
|                                         |            | Female with MID1 mutation 21.3% 20.0%   |
|                                         |            | (26/48) (3/10)                          |
| Developmental delay                     | Absent     | Male with MID1 mutation 54.2% 30.0%     |
|                                         |            | Female with MID1 mutation 21.3% 20.0%   |
|                                         |            | (26/48) (3/10)                          |
| Mental retardation                      | Absent     | Male with MID1 mutation 54.2% 30.0%     |
|                                         |            | Female with MID1 mutation 21.3% 20.0%   |
|                                         |            | (26/48) (3/10)                          |
| Brain abnormality                       | Absent     | Male with MID1 mutation 26.1% 20.0%     |
|                                         |            | Female with MID1 mutation 26.1% 11.1%   |
|                                         |            | (13/36) (1/9)                           |
| Ear abnormality                         | Absent     | Male with MID1 mutation 26.1% 20.0%     |
|                                         |            | Female with MID1 mutation 26.1% 11.1%   |
|                                         |            | (13/36) (1/9)                           |
| Hernia/abdominal wall defect            | Absent     | Male with MID1 mutation 54.2% 30.0%     |
|                                         |            | Female with MID1 mutation 21.3% 20.0%   |
|                                         |            | (26/48) (3/10)                          |
| Cranial/suture abnormality              | Absent     | Male with MID1 mutation 54.2% 30.0%     |
|                                         |            | Female with MID1 mutation 21.3% 20.0%   |
|                                         |            | (26/48) (3/10)                          |
| Renal abnormality                       | Absent     | Male with MID1 mutation 54.2% 30.0%     |
|                                         |            | Female with MID1 mutation 21.3% 20.0%   |
|                                         |            | (26/48) (3/10)                          |
| Skeletal abnormality                    | Absent     | Male with MID1 mutation 54.2% 30.0%     |
|                                         |            | Female with MID1 mutation 21.3% 20.0%   |
|                                         |            | (26/48) (3/10)                          |
| Large fontanel                          | Absent     | Male with MID1 mutation 54.2% 30.0%     |
|                                         |            | Female with MID1 mutation 21.3% 20.0%   |
|                                         |            | (26/48) (3/10)                          |

The TUPLE1 probe for the DiGeorge/VCFs critical region (Vysis, Downers Grove, Ill., U.S.A.) were accomplished according to the manufacturer's specifications with minor modifications. We analyzed 200 interphase nuclei from peripheral blood lymphocytes of the patient.

Mutation analysis

Genomic DNA was extracted from peripheral blood leukocytes with using the Wizard Genomic DNA Purification kit (Promega, Madison, WI, U.S.A.) according to the manufacturer's instructions. All the coding exons and their flanking introns of the MID1 gene were amplified by using primer sets that were designed by the authors (these are available upon request). The polymerase chain reaction (PCR) was performed with a thermal cycler (Model 9700, Applied Biosystems, Foster City, Cal., U.S.A.) as follows: 32 cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec and extension at 72°C for 30 sec. After treating the ampiclon (5 μL) with 10 U shrimp alkaline phosphatase and 2 U exonuclease I (USB Corp., Cleveland, OH, U.S.A.), direct sequencing was performed with the BigDye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) on an ABI Prism 3100 genetic analyzer (Applied Biosystems).

Prenatal diagnosis

After identifying the causative mutation in this family, chorionic villus sampling (CVS) was performed at 74 days of gestation in a 33-yr-old patient's mother (gravida 2, para 1). The DNA was extracted according to standard procedures, and exon 13 of the MID1 gene was sequenced and analyzed on an ABI Prism 3100 genetic analyzer (Applied Biosystems). Cytogenetic analysis was then done by GTG banding. Amniocentesis was carried out for the next pregnancy and the same procedure was done for the CVS.

RESULTS

Mutation analysis

On the FISH analysis, all the cells had two red signals of a similar intensity for TUPLE1 and two green signals of the locus-specific identifier (LSI) ARSA. Mutation analysis of the MID1 gene by direct sequencing of all nine coding exons and intron/exon boundaries identified the c.1798_1799insC mutation in exon 13 (Fig. 1). This mutation is located in the second codon position of the amino acid histidine 600, which produces a frameshift leading to the production of a chimeric 599-residue MID1 protein ending with 12 amino acids that are derived from a wrong reading frame. The patient's mother was a carrier of the same mutation.

Prenatal diagnosis

After identifying the causative mutation in this family, the parents of the patient requested prenatal diagnosis for the next two consecutive fetuses. Genomic DNA was isolated from the chorionic villi of the 2nd baby and from the amniotic fluid of the 3rd baby, and this was subsequently screened for the presence of the c.1798_1799insC mutation by performing sequence analysis of the MID1 exon 13. The mutant-type allele was observed in both fetuses. According to the cyro-
genetic analysis, the 2nd baby was male and this fetus was terminated according to parents’ demand; the 3rd baby was female and delivered.

**DISCUSSION**

In the present study, we report the results of the \( \text{MID1} \) gene mutation analysis that was done in a male patient with XLOS and his mother. After identification of the causative mutation in this family, we successfully performed prenatal diagnosis for the next two fetuses. Our patient had typical phenotypes except for his neurologic abnormalities and congenital heart defects, as compared to those previously reported (5-9). There is considerable clinical variability in the presentation of OS, even among the male patients from the same family who share identical \( \text{MID1} \) mutations (7), and this suggests that other factors modifying the OS phenotype may exist. As far as the genotype/phenotype correlations are concerned, Pinson et al. (10) reported that vermis hypoplasia or agenesis was the most common brain anomaly observed in OS patients with \( \text{MID1} \) mutations, and this has particularly been seen in association with the R495X mutation (\( p<0.0001 \)). So et al. (9) suggested that only laryngo-tracheo-esophageal malformations might correlate with \( \text{MID1} \) mutation. Recently, Mmayer et al. (11) suggested that OS patients with mutations in the FNIII domain of \( \text{MID1} \) retaining residual activity of the FNIII domain would have a milder phenotype without severe brain damage.

Considering the absence of a cure and complete penetrance, prenatal diagnosis appears to be a considerable approach to reduce the burden of this disease on the individual family and also on society. Prenatal diagnosis of OS, including discriminating the sex, is important because the daughters of known or suspected carriers are not likely to be functionally impaired or have an obvious diagnosis of carriers. The finding of hypertelorism as a pervasive sign in the carriers of XLOS, along with a personal or family history of cleft lip, cleft palate or other manifestations of XLOS, may be important as a prenatal screening tool (9). Most XLOS families carry a unique mutation and screening of the whole \( \text{MID1} \) gene is laborious and time consuming. Therefore, prenatal direct mutation analysis can be timely done in those families of which the mutation is known beforehand.

In summary, we found a novel \( \text{MID1} \) mutation in a Korean male patient suffering from XLOS and his mother, and this enabled us to make a successful prenatal diagnosis in this family. To the best of our knowledge, this is the first report on a genetically confirmed case of XLOS in Korea.

**REFERENCES**

1. Opitz JM, Guttenberger JE, Pellet JR. The G syndrome of multiple congenital anomalies. Birth Defects Orig Artic Ser (V) 1969; 2: 95-102.
2. Opitz JM, Smith DW. The BBB syndrome. Familial telecanthus with associated congenital anomalies. Birth Defects Orig Artic Ser (V) 1969; 2: 86-94.
3. Robin NH, Opitz JM, Muenke M. Opitz G/BBB syndrome: clinical comparisons of families linked to Xp22 and 22q, and a review of the literature. Am J Med Genet 1996; 62: 305-17.
4. Robin NH, Feldman GI, Aronson AL, Mitchell HF, Welsberg R, Leonard CO, Burton BK, Josephson KD, Laxova R, Aleck KA, Allanson JE, Guion-Almeida ML, Martin RA, Leichtman LG, Price RA, Opitz JM, Muenke M. Opitz syndrome is genetically heterogeneous, with one locus on Xp22, and a second locus on 22q11.2. Nat Genet 1995; 11: 459-61.
5. Quaderi NA, Schweiger S, Gaudenz K, Franco B, Rugarli EI, Berger W, Feldman GJ, Volta M, Andolfi G, Gilgenkrantz S, Marion RW, Hennekam RC, Opitz JM, Muenke M, Ropers HH, Ballabio A. Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22. Nat Genet 1997; 17: 285-91.

6. Gaudenz K, Roessler E, Quaderi N, Franco B, Feldman G, Gasser DL, Wittwer B, Horst J, Montini E, Opitz JM, Ballabio A, Muenke M. Opitz G/BBB syndrome in Xp22: mutations in the MID1 gene cluster in the carboxy-terminal domain. Am J Hum Genet 1998; 63: 703-10.

7. Cox TC, Allen LR, Cox LL, Hopwood B, Goodwin B, Haan E, Suthers GK. New mutations in MID1 provide support for loss of function as the cause of X-linked Opitz syndrome. Hum Mol Genet 2000; 9: 2553-62.

8. De Falco F, Cainarca S, Andolfi G, Ferrentino R, Bert C, Rodriguez Criado G, Rittinger O, Dennis N, Odeni S, Rastogi A, Liebelt J, Chitayat D, Winter R, Jawanda H, Ballabio A, Franco B, Meroni G. X-linked Opitz syndrome: novel mutations in the MID1 gene and redefinition of the clinical spectrum. Am J Med Genet A 2003; 120: 222-8.

9. So J, Suckow V, Kijas Z, Kalscheuer V, Moser B, Winter J, Baars M, Firth H, Lunt P, Hamel B, Menecke P, Moraine C, Odent S, Schinzel A, van der Smagt JJ, Devriendt K, Albrecht B, Gillessen-Kaesbach G, van der Burgt I, Petrij F, Fuivre L, McGaughran J, McKenzie F, Opitz JM, Cox T, Schweiger S. Mild phenotypes in a series of patients with Opitz GBBB syndrome with MID1 mutations. Am J Med Genet A 2005; 132: 1-7.

10. Pinson L, Auge J, Audollent S, Mattei G, Etchevers H, Gigarel N, Razavi F, Lacombe D, Odent S, Le Merrer M, Amiel J, Munnich A, Meroni G, Lyonnet S, Vekemans M, Attie-Bitach T. Embryonic expression of the human MID1 gene and its mutations in Opitz syndrome. J Med Genet 2004; 41: 381-6.

11. Mnayer L, Khuri S, Al-Ali Merheby H, Meroni G, Elsas LJ. A structure-function study of MID1 mutations associated with a mild Opitz phenotype. Mol Genet Metab 2006; 87: 198-203.